JP2019514907A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514907A5 JP2019514907A5 JP2018556273A JP2018556273A JP2019514907A5 JP 2019514907 A5 JP2019514907 A5 JP 2019514907A5 JP 2018556273 A JP2018556273 A JP 2018556273A JP 2018556273 A JP2018556273 A JP 2018556273A JP 2019514907 A5 JP2019514907 A5 JP 2019514907A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- dose
- statin
- angptl3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 41
- 101710085848 Angiopoietin-related protein 3 Proteins 0.000 claims 18
- 102100025668 Angiopoietin-related protein 3 Human genes 0.000 claims 18
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 17
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims 15
- MBBCVAKAJPKAKM-UHFFFAOYSA-N lomitapide Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1(C(=O)NCC(F)(F)F)CCCCN(CC1)CCC1NC(=O)C1=CC=CC=C1C1=CC=C(C(F)(F)F)C=C1 MBBCVAKAJPKAKM-UHFFFAOYSA-N 0.000 claims 13
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 239000003112 inhibitor Substances 0.000 claims 10
- 108010038232 microsomal triglyceride transfer protein Proteins 0.000 claims 10
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims 9
- 239000003524 antilipemic agent Substances 0.000 claims 8
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims 7
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 201000001386 familial hypercholesterolemia Diseases 0.000 claims 7
- 229960003566 lomitapide Drugs 0.000 claims 7
- 230000001906 cholesterol absorption Effects 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 229940047695 juxtapid Drugs 0.000 claims 6
- 150000002632 lipids Chemical class 0.000 claims 6
- 229960000815 ezetimibe Drugs 0.000 claims 5
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 claims 4
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 4
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 4
- 208000030673 Homozygous familial hypercholesterolemia Diseases 0.000 claims 4
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 4
- 229960005370 atorvastatin Drugs 0.000 claims 4
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 claims 4
- 229940066901 crestor Drugs 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 4
- 229940002661 lipitor Drugs 0.000 claims 4
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 4
- 229960000672 rosuvastatin Drugs 0.000 claims 4
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 4
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 claims 4
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 4
- 229940051223 zetia Drugs 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 230000037396 body weight Effects 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 3
- 101710095342 Apolipoprotein B Proteins 0.000 claims 2
- 102100040202 Apolipoprotein B-100 Human genes 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 229960003765 fluvastatin Drugs 0.000 claims 2
- 229940095570 lescol Drugs 0.000 claims 2
- 229940092923 livalo Drugs 0.000 claims 2
- 229960004844 lovastatin Drugs 0.000 claims 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229940099246 mevacor Drugs 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 229960002797 pitavastatin Drugs 0.000 claims 2
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 2
- RHGYHLPFVJEAOC-FFNUKLMVSA-L pitavastatin calcium Chemical compound [Ca+2].[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1.[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RHGYHLPFVJEAOC-FFNUKLMVSA-L 0.000 claims 2
- 229960002965 pravastatin Drugs 0.000 claims 2
- 229960002855 simvastatin Drugs 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 2
- 229940072168 zocor Drugs 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100040214 Apolipoprotein(a) Human genes 0.000 claims 1
- 101710115418 Apolipoprotein(a) Proteins 0.000 claims 1
- 108010023302 HDL Cholesterol Proteins 0.000 claims 1
- 102000057248 Lipoprotein(a) Human genes 0.000 claims 1
- 108010033266 Lipoprotein(a) Proteins 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229940089484 pravachol Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022145714A JP7404471B2 (ja) | 2016-04-28 | 2022-09-14 | 家族性高コレステロール血症を有する患者を処置するための方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662328823P | 2016-04-28 | 2016-04-28 | |
| US62/328,823 | 2016-04-28 | ||
| US201662348001P | 2016-06-09 | 2016-06-09 | |
| US62/348,001 | 2016-06-09 | ||
| US201762451310P | 2017-01-27 | 2017-01-27 | |
| US62/451,310 | 2017-01-27 | ||
| PCT/US2017/029782 WO2017189813A1 (en) | 2016-04-28 | 2017-04-27 | Methods for treating patients with familial hypercholesterolemia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022145714A Division JP7404471B2 (ja) | 2016-04-28 | 2022-09-14 | 家族性高コレステロール血症を有する患者を処置するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019514907A JP2019514907A (ja) | 2019-06-06 |
| JP2019514907A5 true JP2019514907A5 (OSRAM) | 2020-05-28 |
| JP7201437B2 JP7201437B2 (ja) | 2023-01-10 |
Family
ID=58692626
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018556273A Active JP7201437B2 (ja) | 2016-04-28 | 2017-04-27 | 家族性高コレステロール血症を有する患者を処置するための方法 |
| JP2022145714A Active JP7404471B2 (ja) | 2016-04-28 | 2022-09-14 | 家族性高コレステロール血症を有する患者を処置するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022145714A Active JP7404471B2 (ja) | 2016-04-28 | 2022-09-14 | 家族性高コレステロール血症を有する患者を処置するための方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US20170312359A1 (OSRAM) |
| EP (1) | EP3448426B1 (OSRAM) |
| JP (2) | JP7201437B2 (OSRAM) |
| KR (3) | KR20220148299A (OSRAM) |
| CN (1) | CN109069641A (OSRAM) |
| AU (1) | AU2017258105B2 (OSRAM) |
| CA (1) | CA3021884A1 (OSRAM) |
| DK (1) | DK3448426T3 (OSRAM) |
| ES (1) | ES3032667T3 (OSRAM) |
| FI (1) | FI3448426T3 (OSRAM) |
| HR (1) | HRP20250797T1 (OSRAM) |
| HU (1) | HUE071912T2 (OSRAM) |
| IL (2) | IL262591B (OSRAM) |
| LT (1) | LT3448426T (OSRAM) |
| MA (1) | MA44764B1 (OSRAM) |
| MD (1) | MD3448426T2 (OSRAM) |
| MX (1) | MX2018012741A (OSRAM) |
| PL (1) | PL3448426T3 (OSRAM) |
| PT (1) | PT3448426T (OSRAM) |
| RS (1) | RS66975B1 (OSRAM) |
| SI (1) | SI3448426T1 (OSRAM) |
| SM (1) | SMT202500230T1 (OSRAM) |
| WO (1) | WO2017189813A1 (OSRAM) |
| ZA (1) | ZA201806557B (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR087329A1 (es) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| MA43734A (fr) | 2016-03-03 | 2018-11-28 | Regeneron Pharma | Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3 |
| JP7360716B2 (ja) | 2017-12-01 | 2023-10-13 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用 |
| EP3719126B1 (en) | 2017-12-01 | 2025-01-01 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof |
| EP3718572B1 (en) | 2017-12-01 | 2024-07-31 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method and use |
| HRP20250277T1 (hr) | 2017-12-01 | 2025-05-09 | Suzhou Ribo Life Science Co., Ltd. | Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba |
| CN118291456A (zh) | 2017-12-01 | 2024-07-05 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| EP3732185B1 (en) | 2017-12-29 | 2025-02-26 | Suzhou Ribo Life Science Co., Ltd. | Conjugates and preparation and use thereof |
| CN111655849B (zh) | 2018-08-21 | 2024-05-10 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的药物组合物和缀合物及其用途 |
| EP3862024A4 (en) | 2018-09-30 | 2022-08-17 | Suzhou Ribo Life Science Co., Ltd. | SHORT INTERFERENT RNA CONJUGATE, METHOD FOR PREPARATION AND USE THEREOF |
| WO2020135673A1 (zh) | 2018-12-28 | 2020-07-02 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN112423795A (zh) * | 2018-12-28 | 2021-02-26 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN113227376B (zh) | 2019-05-22 | 2024-04-09 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| US20230045712A1 (en) * | 2019-11-07 | 2023-02-09 | Medimmune, Llc | Endothelial lipase antibodies for the treatment of cardiovascular diseases |
| WO2021154079A1 (en) | 2020-01-29 | 2021-08-05 | Rijksuniversiteit Groningen | Means and methods for modulating lipid metabolism |
| CA3186856A1 (en) | 2020-07-29 | 2022-02-03 | Ruth NALLEN | Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients |
| JP2023538522A (ja) * | 2020-08-07 | 2023-09-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ａｎｇｐｔｌ３阻害剤を伴う難治性高コレステロール血症を処置するための方法 |
| CN112656792B (zh) * | 2021-01-26 | 2022-07-05 | 首都医科大学宣武医院 | 洛美他派在制备用于治疗脑卒中引起的神经损伤药物中的用途 |
| CN116948030B (zh) * | 2022-04-25 | 2024-11-19 | 武汉大学 | 抗asgr1单克隆抗体及其应用 |
| EP4518969A1 (en) | 2022-05-02 | 2025-03-12 | Novo Nordisk A/S | Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutaneous administration |
| CN119192369A (zh) * | 2023-06-25 | 2024-12-27 | 百奥泰生物制药股份有限公司 | 抗angptl3抗体及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US730654A (en) * | 1902-04-17 | 1903-06-09 | John W Hornsey | Hot-air furnace. |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| WO2002067901A1 (en) * | 2001-02-22 | 2002-09-06 | Skyepharma Canada Inc. | Fibrate-statin combinations with reduced fed-fasted effects |
| KR101503937B1 (ko) * | 2006-12-08 | 2015-03-18 | 렉시컨 파마슈티컬스 인코퍼레이티드 | Ａｎｇｐｔｌ３ 에 대한 단일클론 항체 |
| US20130064834A1 (en) * | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| EP2216016A1 (en) * | 2009-02-06 | 2010-08-11 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising ezetimibe |
| EP2521556B1 (en) * | 2010-01-08 | 2018-05-30 | Ionis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
| WO2012168491A1 (en) | 2011-06-10 | 2012-12-13 | Novartis Ag | Pharmaceutical formulations of pcsk9 antagonists |
| AR087329A1 (es) * | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| EP3071198A1 (en) * | 2013-11-20 | 2016-09-28 | Cymabay Therapeutics, Inc. | Treatment of homozygous familial hypercholesterolemia |
| KR102298476B1 (ko) * | 2013-12-24 | 2021-09-03 | 아이오니스 파마수티컬즈, 인코포레이티드 | 안지오포이에틴-유사 3 발현의 조절 |
| CN106255755B (zh) * | 2014-05-01 | 2020-07-24 | Ionis制药公司 | 用于调节血管生成素样蛋白3表达的组合物和方法 |
| MA43734A (fr) * | 2016-03-03 | 2018-11-28 | Regeneron Pharma | Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3 |
| MX386832B (es) * | 2016-04-08 | 2025-03-19 | Regeneron Pharma | Inhibidor angptl8 e inhibidor angptl3 para usarse en el tratamiento de hiperlipidemia. |
-
2017
- 2017-04-27 CN CN201780026147.XA patent/CN109069641A/zh active Pending
- 2017-04-27 IL IL262591A patent/IL262591B/en unknown
- 2017-04-27 MA MA44764A patent/MA44764B1/fr unknown
- 2017-04-27 JP JP2018556273A patent/JP7201437B2/ja active Active
- 2017-04-27 EP EP17722604.0A patent/EP3448426B1/en active Active
- 2017-04-27 MX MX2018012741A patent/MX2018012741A/es unknown
- 2017-04-27 AU AU2017258105A patent/AU2017258105B2/en active Active
- 2017-04-27 FI FIEP17722604.0T patent/FI3448426T3/fi active
- 2017-04-27 KR KR1020227036013A patent/KR20220148299A/ko not_active Ceased
- 2017-04-27 HU HUE17722604A patent/HUE071912T2/hu unknown
- 2017-04-27 KR KR1020187034616A patent/KR20190003679A/ko not_active Ceased
- 2017-04-27 SM SM20250230T patent/SMT202500230T1/it unknown
- 2017-04-27 PL PL17722604.0T patent/PL3448426T3/pl unknown
- 2017-04-27 KR KR1020247003356A patent/KR20240019856A/ko active Pending
- 2017-04-27 LT LTEPPCT/US2017/029782T patent/LT3448426T/lt unknown
- 2017-04-27 DK DK17722604.0T patent/DK3448426T3/da active
- 2017-04-27 RS RS20250643A patent/RS66975B1/sr unknown
- 2017-04-27 IL IL293308A patent/IL293308B2/en unknown
- 2017-04-27 ES ES17722604T patent/ES3032667T3/es active Active
- 2017-04-27 HR HRP20250797TT patent/HRP20250797T1/hr unknown
- 2017-04-27 US US15/498,687 patent/US20170312359A1/en not_active Abandoned
- 2017-04-27 WO PCT/US2017/029782 patent/WO2017189813A1/en not_active Ceased
- 2017-04-27 PT PT177226040T patent/PT3448426T/pt unknown
- 2017-04-27 SI SI201731609T patent/SI3448426T1/sl unknown
- 2017-04-27 CA CA3021884A patent/CA3021884A1/en active Pending
- 2017-04-27 MD MDE20190270T patent/MD3448426T2/ro unknown
-
2018
- 2018-10-03 ZA ZA2018/06557A patent/ZA201806557B/en unknown
-
2019
- 2019-11-07 US US16/677,319 patent/US20200061189A1/en not_active Abandoned
-
2022
- 2022-07-07 US US17/859,996 patent/US20230000976A1/en not_active Abandoned
- 2022-09-14 JP JP2022145714A patent/JP7404471B2/ja active Active
-
2025
- 2025-07-14 US US19/268,651 patent/US20250332254A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019514907A5 (OSRAM) | ||
| JP2022177142A5 (OSRAM) | ||
| JP7404471B2 (ja) | 家族性高コレステロール血症を有する患者を処置するための方法 | |
| RU2013139727A (ru) | Антитела человека к pcsk9 для применения в способах лечения конкретных групп индивидуумов | |
| JP2014516953A5 (OSRAM) | ||
| CN103732624B (zh) | 抗angptl3抗体及其用途 | |
| JP2017528427A5 (OSRAM) | ||
| JP2013023499A5 (OSRAM) | ||
| HRP20200545T1 (hr) | Postupci liječenja ili sprječavanja poremećaja povezanih sa kolesterolom | |
| JP2017506626A5 (OSRAM) | ||
| JP2016538248A5 (OSRAM) | ||
| JP2016520616A5 (OSRAM) | ||
| IL277127B1 (en) | Using pcsk9 tracking to reduce cardiovascular risk | |
| JP2016538277A5 (OSRAM) | ||
| JP2015530867A5 (OSRAM) | ||
| JP2019512472A5 (OSRAM) | ||
| RU2017104800A (ru) | Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh) | |
| JP2016523847A5 (OSRAM) | ||
| JP2019513751A5 (OSRAM) | ||
| JP2017522316A5 (OSRAM) | ||
| JP2022000443A5 (OSRAM) | ||
| RU2015101113A (ru) | Антитела против pcsk9, составы, дозы и способы применения | |
| RU2013156848A (ru) | Лечение антителами против pcsk9 | |
| JP2018138551A (ja) | 関節リウマチの治療 | |
| JP2024059787A (ja) | Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法 |